{"id":126,"date":"2023-09-20T12:48:35","date_gmt":"2023-09-20T03:48:35","guid":{"rendered":"http:\/\/www.lifescience.shokubai.co.jp\/home\/service03\/"},"modified":"2026-05-26T14:21:48","modified_gmt":"2026-05-26T05:21:48","slug":"dds-research","status":"publish","type":"page","link":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/","title":{"rendered":"Support for Drug Development"},"content":{"rendered":"\n<section class=\"service03_contents_01 service_page_contents inner-container\">\n  <ul>\n    <li class=\"list_3\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n          Peptides that deliver siRNA<br><span>DDS technology for selectively delivering siRNA to pancreatic cancer, etc.<\/span>\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n          Fol-Dab8 is innovative DDS technology that forms a complex with siRNA and delivers siRNA to folate receptor-expressing cells (pancreatic cancer, brain tumors, breast cancer, etc.).\n          Fol-Dab8 is available in a form of complex with siRNA of any sequence.<br \/>\n          *This technology was co-developed with Dr. Takeshi Wada of Tokyo University of Science and Dr. Keisuke Taniuchi of Kochi University.<br \/>\n          *Fol-Dab8 is an abbreviation for 2,4-diaminobutyric acid (Dab) octamer with folic acid (Folate) linked via a linker.<br \/>\n        <\/p>  \n        <div class=\"btnBox pc\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/05\/Fol-Dab8_en.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About Fol-Dab8<\/a>\n        <\/div>\n        <div class=\"btnBox sp-f\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/05\/Fol-Dab8_en.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About Fol-Dab8<\/a>\n        <\/div>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox tab-hide\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/Fol-Dab8_en.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/1d715ba4c163e4537712deeb22b376fd.png\" alt=\"\">\n        <\/picture>\n        <picture class=\"imgBox tab-t\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/Fol-Dab8_en_sp.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/1d715ba4c163e4537712deeb22b376fd.png\" alt=\"\">\n        <\/picture>\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n\n    <li class=\"list_3\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n          New biocompatible polymer(For DDS and others)<br><span>A new option following polyethylene glycol.<\/span>\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n          A novel biocompatible polymer &#8220;PGLMMA&#8221; offers numerous advantages, such as being less likely to induce IgM antibody production and maintaining blood retention even after multiple doses.<br\/>\n         *PGLMMA is an abbreviation for poly (glycerol monomethacrylate). \n        <\/p>\n        <div class=\"btnBox pc\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/05\/PGLMMA_en-1.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About PGLMMA<\/a>\n        <\/div>\n        <div class=\"btnBox sp-f\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/05\/PGLMMA_en-1.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About PGLMMA<\/a>\n        <\/div>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/PGLMMA_en.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/170f25249c652c2a36b5febc3e8ad474.png\" alt=\"\">\n        <\/picture>\n\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n\n    <li class=\"list_3\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n         Heteroduplex Oligonucleotides<span> (HDO)<\/span>\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n Heteroduplex oligonucleotide (HDO) is the third platform technology for mRNA Therapeutics following short interfering RNA (siRNA) and single-stranded antisense oligonucleotide (ASO), which serves as a therapeutic agent for the modulation of specific genes at the post-transcriptional level. HDO is an artificial functioning nucleic acids composed of an antisense strand (gapmer, mixmer, PMO etc.) that binds to a transcript of a target gene and a carrier strand (RNA) that is complementary to the antisense strand. Since a ligand (receptor ligands, antibodies, lipids, etc.) is bound to the carrier strand, various ligands can be introduced without affecting the activity of the antisense strand enabling cell-specific delivery. HDO has high nuclear localization and low toxicity compared to ASO.\n        <\/p>\n       <div class=\"btnBox pc\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/05\/HDO_trial_en.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About HDO trial service<\/a>\n        <\/div>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img03.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img03.png\" alt=\"\">\n        <\/picture>\n        <div class=\"innerBox_01\">\n          <picture class=\"imgBox\">\n            <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/02\/service03_img03-2.webp\" type=\"image\/webp\">\n            <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/02\/service03_img03-2-1.png\" alt=\"\">\n          <\/picture>\n          <ul class=\"lower_contents_summary\">\n            <li>Rena Therapeutics uses heteroduplex oligonucleotide (HDO) technology as its base technology. HDO technology was co-developed by Professor Takanori Yokota of Institute of Science Tokyo and Professor Satoshi Obika of Osaka University. <\/li>\n            <li>Rena Therapeutics is a subsidiary of Nippon Shokubai.<\/li>\n          <\/ul>\n        <\/div><!-- \/.innerBox -->\n         <div class=\"btnBox sp-f\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/05\/HDO_trial_en.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About HDO trial service<\/a>\n        <\/div>\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n    <li class=\"list_4\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n          Boranophosphate Oligonucleotides\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n          We are developing chemical synthesis techniques and practical manufacturing methods for boranophosphate oligonucleotides, which have a new structure to replace conventional phosphorothioate oligonucleotides. \n        <\/p>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img04.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img04.png\" alt=\"\">\n        <\/picture>\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n  <\/ul>\n\n\n<\/section><!-- \/.service01_contents_01 -->\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peptides that deliver siRNADDS technology for selectively delivering siRNA to pancreatic cancer, etc. Fol-Dab8 is innovative DDS technology that forms a complex with siRNA and delivers siRNA to folate receptor-expressing cells (pancreatic cancer, brain tumors, breast cancer, etc.). Fol-Dab8 is available in a form of complex with siRNA of any sequence. *This technology was co-developed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-126","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"NIPPON SHOKUBAI | Nippon Shokubai\u2019s Health &amp; Medical Business Division provides contract manufacturing (CDMO) of oligonucleotide and peptide APIs, process development, analytical development, and supports DDS research and drug discovery. We contribute to the next generation of drug modality with our technology.\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Support for Drug Development | NIPPON SHOKUBAI\" \/>\n\t\t<meta property=\"og:description\" content=\"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-09-20T03:48:35+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-05-26T05:21:48+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Support for Drug Development | NIPPON SHOKUBAI\" \/>\n\t\t<meta name=\"twitter:description\" content=\"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/dds-research\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/#listItem\",\"position\":1,\"name\":\"\\u5bb6\",\"item\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/dds-research\\\/#listItem\",\"name\":\"Support for Drug Development\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/dds-research\\\/#listItem\",\"position\":2,\"name\":\"Support for Drug Development\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/#listItem\",\"name\":\"\\u5bb6\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/#organization\",\"name\":\"\\u682a\\u5f0f\\u4f1a\\u793e\\u65e5\\u672c\\u89e6\\u5a92\",\"description\":\"Nippon Shokubai\\u2019s Health & Medical Business Division provides contract manufacturing (CDMO) of oligonucleotide and peptide APIs, process development, analytical development, and supports DDS research and drug discovery. We contribute to the next generation of drug modality with our technology.\",\"url\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/dds-research\\\/#webpage\",\"url\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/dds-research\\\/\",\"name\":\"Support for Drug Development | NIPPON SHOKUBAI\",\"description\":\"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/dds-research\\\/#breadcrumblist\"},\"datePublished\":\"2023-09-20T12:48:35+09:00\",\"dateModified\":\"2026-05-26T14:21:48+09:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/\",\"name\":\"\\u682a\\u5f0f\\u4f1a\\u793e\\u65e5\\u672c\\u89e6\\u5a92\",\"description\":\"Nippon Shokubai\\u2019s Health & Medical Business Division provides contract manufacturing (CDMO) of oligonucleotide and peptide APIs, process development, analytical development, and supports DDS research and drug discovery. We contribute to the next generation of drug modality with our technology.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.lifescience.shokubai.co.jp\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Support for Drug Development | NIPPON SHOKUBAI","description":"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.","canonical_url":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/#listItem","position":1,"name":"\u5bb6","item":"https:\/\/www.lifescience.shokubai.co.jp\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/#listItem","name":"Support for Drug Development"}},{"@type":"ListItem","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/#listItem","position":2,"name":"Support for Drug Development","previousItem":{"@type":"ListItem","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/#listItem","name":"\u5bb6"}}]},{"@type":"Organization","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/#organization","name":"\u682a\u5f0f\u4f1a\u793e\u65e5\u672c\u89e6\u5a92","description":"Nippon Shokubai\u2019s Health & Medical Business Division provides contract manufacturing (CDMO) of oligonucleotide and peptide APIs, process development, analytical development, and supports DDS research and drug discovery. We contribute to the next generation of drug modality with our technology.","url":"https:\/\/www.lifescience.shokubai.co.jp\/en\/"},{"@type":"WebPage","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/#webpage","url":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/","name":"Support for Drug Development | NIPPON SHOKUBAI","description":"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/#website"},"breadcrumb":{"@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/#breadcrumblist"},"datePublished":"2023-09-20T12:48:35+09:00","dateModified":"2026-05-26T14:21:48+09:00"},{"@type":"WebSite","@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/#website","url":"https:\/\/www.lifescience.shokubai.co.jp\/en\/","name":"\u682a\u5f0f\u4f1a\u793e\u65e5\u672c\u89e6\u5a92","description":"Nippon Shokubai\u2019s Health & Medical Business Division provides contract manufacturing (CDMO) of oligonucleotide and peptide APIs, process development, analytical development, and supports DDS research and drug discovery. We contribute to the next generation of drug modality with our technology.","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.lifescience.shokubai.co.jp\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"NIPPON SHOKUBAI | Nippon Shokubai\u2019s Health &amp; Medical Business Division provides contract manufacturing (CDMO) of oligonucleotide and peptide APIs, process development, analytical development, and supports DDS research and drug discovery. We contribute to the next generation of drug modality with our technology.","og:type":"article","og:title":"Support for Drug Development | NIPPON SHOKUBAI","og:description":"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.","og:url":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/","article:published_time":"2023-09-20T03:48:35+00:00","article:modified_time":"2026-05-26T05:21:48+00:00","twitter:card":"summary_large_image","twitter:title":"Support for Drug Development | NIPPON SHOKUBAI","twitter:description":"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own."},"aioseo_meta_data":{"post_id":"126","title":null,"description":"We actively collaborate with promising domestic venture companies and focus on the development of cutting-edge and original research and technology, such as DDS technology development based on HDO (Heteroduplex Oligonucleotides) technology and DDS polymer development of our own.","keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2023-09-30 07:21:54","updated":"2026-05-26 05:35:03","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.lifescience.shokubai.co.jp\/en\/\" title=\"\u5bb6\">\u5bb6<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tSupport for Drug Development\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"\u5bb6","link":"https:\/\/www.lifescience.shokubai.co.jp\/en\/"},{"label":"Support for Drug Development","link":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/"}],"_links":{"self":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages\/126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/comments?post=126"}],"version-history":[{"count":2,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages\/126\/revisions"}],"predecessor-version":[{"id":2368,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages\/126\/revisions\/2368"}],"wp:attachment":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/media?parent=126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}